# Federal Cannabis Regulatory Updates: March 14, 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/federal-cannabis-regulatory-updates-march-14-2026/ > **Published:** 2026-03-14T19:05:03-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:07:38-04:00 > **Clinical Summary:** Stay informed on federal cannabis regulatory updates including DEA scheduling and Medicare policies impacting cannabis clinicians and patients in 2026. --- Policy WatchMarch 14, 2026. 17 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.gov [Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I](https://www.regulations.gov/document/DEA-2024-0026-0001) Regulatory Summary The DEA placed 2-Methyl AP-237 (synthetic opioid) in Schedule I, establishing it as illegal with no medical use—relevant to cannabis clinicians managing pain patients seeking [alternative therapies](https://cedclinic.com/medical-cannabis-eligibility-book-appointment/). [Read more →](https://www.regulations.gov/document/DEA-2024-0026-0001) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I](https://www.regulations.gov/document/DEA-2023-0168-0001) This DEA scheduling action places synthetic amphetamines in Schedule I and has no direct relevance to cannabis clinicians or patients, as it addresses different controlled substances unrelated to cannabis regulation. [Read more →](https://www.regulations.gov/document/DEA-2023-0168-0001) Score 70Regulations.gov [Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I](https://www.regulations.gov/document/DEA-2023-0049-0004) The DEA temporarily placed six synthetic cannabinoids into Schedule I, restricting their legal availability and potentially affecting cannabis clinicians’ understanding of emerging cannabinoid compounds and patient access to unregulated alternatives. [Read more →](https://www.regulations.gov/document/DEA-2023-0049-0004) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0001) This DEA action scheduling ethylphenidate has minimal direct relevance to cannabis clinicians or patients, as it addresses a synthetic stimulant rather than cannabis or cannabinoid therapeutics. [Read more →](https://www.regulations.gov/document/DEA-2023-0129-0001) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Metonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0005) Regulatory Summary This action schedules metonitazene (a synthetic opioid) under Schedule I, establishing controlled substance regulations unrelated to cannabis medical practice or patient care. [Read more →](https://www.regulations.gov/document/DEA-2021-0031-0005) Score 70Regulations.gov [Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I](https://www.regulations.gov/document/DEA-2022-0145-0004) This regulatory action schedules benzodiazepine analogs as controlled substances, directly relevant to cannabis clinicians managing anxiety or seizure disorders who may need to adjust treatment protocols or patient referrals for these conditions. [Read more →](https://www.regulations.gov/document/DEA-2022-0145-0004) Score 70Regulations.gov [Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224](https://www.regulations.gov/document/DEA-2023-0096-0001) Regulatory Summary DEA Form 1224 permits biopharmaceutical companies to import controlled substances for research, directly enabling [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and pharmaceutical development of cannabis-derived medicines for patients. [Read more →](https://www.regulations.gov/document/DEA-2023-0096-0001) Score 55Regulations.gov [Importer of Controlled-Bright Green(2024-20083)DEA1426](https://www.regulations.gov/document/DEA-2024-0111-0001) Regulatory Summary This DEA importer registration (2024-20083) permits controlled substance importation; cannabis clinicians should verify supplier licensing compliance when sourcing cannabis-derived medicines or research materials. [Read more →](https://www.regulations.gov/document/DEA-2024-0111-0001) Score 55Regulations.gov [Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429](https://www.regulations.gov/document/DEA-2024-0110-0001) Regulatory Summary DEA permit (2024-20082) authorizes Cambridge Isotope as a controlled substance importer, potentially enabling research into cannabis metabolite tracking and cannabinoid labeling studies relevant to clinical pharmacology. [Read more →](https://www.regulations.gov/document/DEA-2024-0110-0001) Score 55Regulations.gov [Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.](https://www.regulations.gov/document/CMS-2024-0256-0045) CMS establishes 2025 Medicare/Medicaid reimbursement rates and coverage policies, potentially affecting cannabis clinician billing codes and patient access to cannabis-derived treatments under federal insurance programs. [Read more →](https://www.regulations.gov/document/CMS-2024-0256-0045) Score 55Regulations.gov [Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)](https://www.regulations.gov/document/CMS-2024-0256-0001) CMS proposed 2025 Medicare payment policy updates; [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) remains federally non-covered, so this rule does not directly affect cannabis clinician reimbursement or patient access through Medicare/Medicaid programs. [Read more →](https://www.regulations.gov/document/CMS-2024-0256-0001) Score 55Regulations.gov [Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368](https://www.regulations.gov/document/DEA-2024-0060-0001) Regulatory Summary DEA registration 2024-11786 authorizes Royal Emerald as a bulk manufacturer, enabling increased production capacity for cannabis-derived pharmaceutical compounds used in clinical and patient treatment contexts. [Read more →](https://www.regulations.gov/document/DEA-2024-0060-0001) Score 55Regulations.gov [Importer Controlled-VA Cooperative (2024-11795) DEA1374](https://www.regulations.gov/document/DEA-2024-0064-0001) Regulatory Summary The DEA document establishes importer controlled substance cooperative frameworks, directly affecting cannabis clinicians’ and patients’ access to regulated cannabis products through licensed distribution channels. [Read more →](https://www.regulations.gov/document/DEA-2024-0064-0001) Score 55Regulations.gov [Importer Controlled- Quagen Pharma (2024-11892) DEA1381](https://www.regulations.gov/document/DEA-2024-0070-0001) Regulatory Summary DEA Form 1381 filing indicates Quagen Pharma’s controlled substance importation status, relevant to cannabis clinicians regarding supply chain oversight and pharmaceutical-grade cannabis product availability. [Read more →](https://www.regulations.gov/document/DEA-2024-0070-0001) Score 55Regulations.gov [Exempt Chemical Preparations May 2024 (2024-10465) – DEA372](https://www.regulations.gov/document/DEA-2022-0002-0006) Regulatory Summary The DEA updated exempt chemical preparations guidance in May 2024, potentially clarifying which cannabis-derived or cannabis-adjacent compounds may be exempt from controlled substance regulations, affecting clinical prescribing authority and patient access. [Read more →](https://www.regulations.gov/document/DEA-2022-0002-0006) Score 55Regulations.gov [Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-F)](https://www.regulations.gov/document/CMS-2023-0121-22025) Regulatory Relevance to [Cannabis Medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) This CMS final rule establishes 2024 Medicare payment policies and coverage requirements that may affect cannabis-derived medication reimbursement and prescribing practices within Medicare and Medicaid programs. [Read more →](https://www.regulations.gov/document/CMS-2023-0121-22025) Score 55Regulations.gov [Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-P)](https://www.regulations.gov/document/CMS-2023-0121-0001) This CMS rule updates Medicare/Medicaid payment policies and coverage requirements but does not directly address cannabis; however, it may affect reimbursement considerations for cannabis-related medical services under Medicare Part B. [Read more →](https://www.regulations.gov/document/CMS-2023-0121-0001) Digest-Level Clinical Commentary Dr. Caplan’s Take These regulatory items collectively signal that federal cannabis policy remains fragmented and static while the DEA intensifies enforcement against novel synthetic cannabinoids and other designer drugs, suggesting that legitimate cannabis medicine practitioners should expect continued operational uncertainty regarding prescribing authority, insurance reimbursement through Medicare and Medicaid, and the lack of any federal advancement toward rescheduling that would align with state-legal [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs. The emphasis on synthetic cannabinoid scheduling reflects escalating public health concerns about unregulated products, which underscores why evidence-based cannabis medicine education and patient safety protocols are increasingly important despite the absence of federal legitimacy. Clinicians practicing cannabis medicine should anticipate that reimbursement barriers will persist, clinical guidance will remain primarily informed by state law and peer-reviewed literature rather than federal approval, and the regulatory landscape will continue to prioritize supply chain oversight of Clinical Perspective These regulatory notices reflect ongoing federal efforts to control emerging synthetic drugs and designer compounds that pose public health risks, while simultaneously managing the infrastructure for legitimate pharmaceutical manufacturing and distribution of controlled substances. The dominance of scheduling actions for novel synthetic cannabinoids and benzodiazepines indicates that clandestine chemists continue to circumvent existing regulations through structural modifications, requiring periodic administrative responses to keep pace with these evolving products. The parallel approvals for pharmaceutical importers and manufacturers suggest that despite these enforcement activities, the healthcare system maintains stable access to legitimately produced controlled medications through established regulatory pathways. Controlled SubstancesDrug SchedulingRegulatory ComplianceDEA Administration 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+March+14%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+March+14%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [This Week in Cannabis: March 13, 2026](https://cedclinic.com/marijuana-reclassification-drug-testing-impacts-2026/) - [New Hampshire House Lets Marijuana Legalization And Psilocybin Therapy Bills Die Without A Vote](https://cedclinic.com/psilocybin-therapy-legislation-new-hampshire-impact/) - [A Beginner’s Guide to Reading Cannabis Certificates of Analysis in Florida](https://cedclinic.com/certificate-of-analysis-cannabis-florida-guide/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Policy Watch: 20 Regulatory Updates — March 14, 2026](https://cedclinic.com/dea-marijuana-schedule-change-2026-regulatory-update/) Explore additional regulatory updates from March 14, 2026, providing broader insights into federal cannabis policy changes. [Read More](https://cedclinic.com/dea-marijuana-schedule-change-2026-regulatory-update/) [Policy Watch: 17 Regulatory Updates — March 17, 2026](https://cedclinic.com/cannabis-medicine-regulatory-updates-march-17-2026/) Stay current with the latest federal cannabis regulatory developments following the March 14 updates. [Explore Updates](https://cedclinic.com/cannabis-medicine-regulatory-updates-march-17-2026/) [Policy Watch: 16 Regulatory Updates — March 13, 2026](https://cedclinic.com/cannabis-medicine-regulations-2026-march-13-updates/) Review the prior day's regulatory updates to understand the evolving federal cannabis landscape. [Learn More](https://cedclinic.com/cannabis-medicine-regulations-2026-march-13-updates/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).